Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Intervacc AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 23.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Intervacc AB's 3-Year ROIIC % or its related term are showing as below:
FRA:2E9's 3-Year ROIIC % is ranked better than 66.41% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs FRA:2E9: 23.66
Intervacc AB (FRA:2E9) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Intervacc AB 3-Year ROIIC % Related Terms
Intervacc AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Intervacc AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Intervacc AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Intervacc AB's 3-Year ROIIC % falls into.
Intervacc AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -7.673 (Dec. 2025) - -5.859 (Dec. 2022) )
/
( 12.228 (Dec. 2025) - 19.44 (Dec. 2022) )
=
-1.814
/
-7.212
=
25.15%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Intervacc AB (FRA:2E9) has a 3-Year ROIIC % of 23.66 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Intervacc AB and its competitors. According to the industry distribution chart, Intervacc AB ranks #444 out of 1322 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Intervacc AB's 3-Year ROIIC % too high?
Intervacc AB's current 3-Year ROIIC % is 23.66. Based on the distribution chart, Intervacc AB ranks #444 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #444 out of 1322 companies for 3-Year ROIIC %. This puts Intervacc AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Intervacc AB and its competitors. Intervacc AB's current 3-Year ROIIC % is 23.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current 3-Year ROIIC % of 23.66. The stock's GF Value™ is €0.09, compared to a current price of €0.09 — trading right at its estimated fair value. The current 3-Year ROIIC % is 23.66. Intervacc AB's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current 3-Year ROIIC % is 23.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be undervalued.
The current stock price of €0.09 is trading 0% below its estimated GF Value™ of €0.09.
Key valuation signals for FRA:2E9:
3-Year ROIIC %: 23.66
GF Value™: €0.09 vs. price of €0.09 (0% below fair value)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score
Get the complete analysis for FRA:2E9
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
